Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy

Cancer Gene Therapy

Volumn 14, Issue 1, 2007, Pages 57-65

  Richard, C ^a,b   Duivenvoorden, W ^a,b   Bourbeau, D ^c   Massie, B ^c,d,e   Roa, W ^f   Yau, J ^g   Th'ng, J ^a,b,h  

^a THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^b LAKEHEAD UNIVERSITY   (Canada)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

5 FU resistance; Adenovirus; Cytosine deaminase; Primary tumors; Suicide gene therapy; Uracil phosphoribosyl transferase

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CYTOSINE DEAMINASE; DOXORUBICIN; FLUCYTOSINE; FLUOROURACIL; PACLITAXEL; URACIL PHOSPHORIBOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; ASCITES; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PLEURA FLUID; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR; TUMOR CELL; VIRAL GENE THERAPY; XENOGRAFT;

ADENOVIRIDAE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE THERAPY; HUMANS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 33845638806     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700980     Document Type: Article

References (33)

1. Miyagi T, Koshida K, Hori O, Konaka H, Katoh H, Kitagawa Y et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med 2003; 5: 30-37.
2. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Therapy 2001; 8: 1547-1554.
3. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015-1022.
4. Yazawa K, Fisher WE, Brunicardi FC. Current Progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783-789.
5. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8: S68-S73.
6. Ramnaraine M, Pan W, Goblirsch M, Lynch C, Lewis V, Orchard P et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003; 63: 6847-6854.
7. Kawamura K, Bahar R, Namba H, Seimiya M, Takenaga K, Hamada H et al. Bystander effect in uracil phosphoribosyltransferase/phosphoribosyltransferase/ 5-fluorouracil-mediated suicide gene therapy is correlated with the level of intracellular communication. Int J Oncol 2001; 18: 117-120.
8. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997; 33: 1005-1016.
9. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003; 2003: 48-70.
10. Bourbeau D, Lavoie G, Nalbantoglu J, Massie B. Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status. J Gene Med 2004; 6: 1320-1332.
11. Nishiyama T, Kawamura Y, Kawamoto K, Matsumuru H, Yamamoto N, Ito T et al. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res 1985; 45: 1753-1761.
12. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
13. Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951.
14. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 176: 41-49.
15. Grem JL. 5-Fluorouracil: fourty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000; 18: 299-313.
16. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 2000; 1: 137-164.
17. Mader RM, Muller M, Steger GG. Resistance to 5-fluorouracil. Gen Pharmacol 1998; 31: 661-666.
18. Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 1998; 25: 887-895.
19. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9: 4116-4124.
20. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL et al. Introduction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
21. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD et al. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Therapy 2002; 9: 844-849.
22. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002; 62: 773-780.
23. Kato H, Koshida K, Yokoyama K, Mizokami A, Namiki M. Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study. Int J Urol 2002; 9: 567-576.
24. Kurosumi K, Tamiya T, Ono Y, Otsuka S, Kambara H, Adachi Y et al. Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol 2004; 66: 117-127.
25. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
26. Richard C, Matthews D, Duivenvoorden W, Yau J, Wright PS, Th'ng JPH. Flavopiridol sensitivityof cancer cells isolated from ascites and pleural fluids. Clin Cancer Res 2005; 11: 3523-3529.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immuno Methods 1983; 65: 55-63.
28. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63: 4602-4606.
29. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-362.
30. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10: 2158-2167.
31. Akbulut H, Tang Y, Maynard J, Zhang L, Pizzorno G, Deisseroth A. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin Cancer Res 2004; 10: 7738-7746.
32. Chung YM, Park SH, Park JK, Kim YT, Kang YK, Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000; 159: 95-101.
33. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 1486-1492.